NCT06063018View on ClinicalTrials.gov

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Cervical Cancer Recurrent
Interventions
DRUG

RC48 + Tislelizumab

RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER